CovidChloroV1, Main, Exploration, bibRecord, 001077

In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials.

Identifieur interne : 001077 ( Main/Exploration ); précédent : 001076; suivant : 001078

In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials.

Auteurs : Seref Gul [Turquie] ; Onur Ozcan [Turquie] ; Sinan Asar [Turquie] ; Alper Okyar [Turquie] ; Ibrahim Bar S [Turquie] ; Ibrahim Halil Kavakli [Turquie]

Source :

Journal of biomolecular structure & dynamics [ 1538-0254 ] ; 2020.

RBID : pubmed:32752938

Abstract

Despite strict measures taken by many countries, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be an issue of global concern. Currently, there are no clinically proven pharmacotherapies for coronavirus disease 2019, despite promising initial results obtained from drugs such as azithromycin and hydroxychloroquine. Therefore, the repurposing of clinically approved drugs for use against SARS-CoV-2 has become a viable strategy. Here, we searched for drugs that target SARS-CoV-2 3C-like protease (3CL^pro) and viral RNA-dependent RNA polymerase (RdRp) by in silico screening of the U.S. Food and Drug Administration approved drug library. Well-tolerated and widely used drugs were selected for molecular dynamics (MD) simulations to evaluate drug-protein interactions and their persistence under physiological conditions. Tetracycline, dihydroergotamine, ergotamine, dutasteride, nelfinavir, and paliperidone formed stable interactions with 3CL^pro based on MD simulation results. Similar analysis with RdRp showed that eltrombopag, tipranavir, ergotamine, and conivaptan bound to the enzyme with high binding free energies. Docking results suggest that ergotamine, dihydroergotamine, bromocriptine, dutasteride, conivaptan, paliperidone, and tipranavir can bind to both enzymes with high affinity. As these drugs are well tolerated, cost-effective, and widely used, our study suggests that they could potentially to be used in clinical trials for the treatment of SARS-CoV-2-infected patients. Communicated by Ramaswamy H. Sarma.

DOI: 10.1080/07391102.2020.1802346
PubMed: 32752938
PubMed Central: PMC7484590

Affiliations:

Turquie

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000F89
to stream Main, to step Curation: 000F89

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials.</title>
<author><name sortKey="Gul, Seref" sort="Gul, Seref" uniqKey="Gul S" first="Seref" last="Gul">Seref Gul</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Chemical and Biological Engineering, Koc University, Istanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Chemical and Biological Engineering, Koc University, Istanbul</wicri:regionArea>
<wicri:noRegion>Istanbul</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ozcan, Onur" sort="Ozcan, Onur" uniqKey="Ozcan O" first="Onur" last="Ozcan">Onur Ozcan</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Biology and Genetics, Koc University, Istanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Molecular Biology and Genetics, Koc University, Istanbul</wicri:regionArea>
<wicri:noRegion>Istanbul</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Asar, Sinan" sort="Asar, Sinan" uniqKey="Asar S" first="Sinan" last="Asar">Sinan Asar</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Anesthesiology and Reanimation, Bakırköy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Anesthesiology and Reanimation, Bakırköy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul</wicri:regionArea>
<wicri:noRegion>Istanbul</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Okyar, Alper" sort="Okyar, Alper" uniqKey="Okyar A" first="Alper" last="Okyar">Alper Okyar</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, Istanbul University Faculty of Pharmacy, Istanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pharmacology, Istanbul University Faculty of Pharmacy, Istanbul</wicri:regionArea>
<wicri:noRegion>Istanbul</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bar S, Ibrahim" sort="Bar S, Ibrahim" uniqKey="Bar S I" first="Ibrahim" last="Bar S">Ibrahim Bar S</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Biology and Genetics, Koc University, Istanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Molecular Biology and Genetics, Koc University, Istanbul</wicri:regionArea>
<wicri:noRegion>Istanbul</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kavakli, Ibrahim Halil" sort="Kavakli, Ibrahim Halil" uniqKey="Kavakli I" first="Ibrahim Halil" last="Kavakli">Ibrahim Halil Kavakli</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Chemical and Biological Engineering, Koc University, Istanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Chemical and Biological Engineering, Koc University, Istanbul</wicri:regionArea>
<wicri:noRegion>Istanbul</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Biology and Genetics, Koc University, Istanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Molecular Biology and Genetics, Koc University, Istanbul</wicri:regionArea>
<wicri:noRegion>Istanbul</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32752938</idno>
<idno type="pmid">32752938</idno>
<idno type="doi">10.1080/07391102.2020.1802346</idno>
<idno type="pmc">PMC7484590</idno>
<idno type="wicri:Area/Main/Corpus">000F89</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000F89</idno>
<idno type="wicri:Area/Main/Curation">000F89</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000F89</idno>
<idno type="wicri:Area/Main/Exploration">000F89</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials.</title>
<author><name sortKey="Gul, Seref" sort="Gul, Seref" uniqKey="Gul S" first="Seref" last="Gul">Seref Gul</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Chemical and Biological Engineering, Koc University, Istanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Chemical and Biological Engineering, Koc University, Istanbul</wicri:regionArea>
<wicri:noRegion>Istanbul</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ozcan, Onur" sort="Ozcan, Onur" uniqKey="Ozcan O" first="Onur" last="Ozcan">Onur Ozcan</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Biology and Genetics, Koc University, Istanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Molecular Biology and Genetics, Koc University, Istanbul</wicri:regionArea>
<wicri:noRegion>Istanbul</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Asar, Sinan" sort="Asar, Sinan" uniqKey="Asar S" first="Sinan" last="Asar">Sinan Asar</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Anesthesiology and Reanimation, Bakırköy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Anesthesiology and Reanimation, Bakırköy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul</wicri:regionArea>
<wicri:noRegion>Istanbul</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Okyar, Alper" sort="Okyar, Alper" uniqKey="Okyar A" first="Alper" last="Okyar">Alper Okyar</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, Istanbul University Faculty of Pharmacy, Istanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pharmacology, Istanbul University Faculty of Pharmacy, Istanbul</wicri:regionArea>
<wicri:noRegion>Istanbul</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bar S, Ibrahim" sort="Bar S, Ibrahim" uniqKey="Bar S I" first="Ibrahim" last="Bar S">Ibrahim Bar S</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Biology and Genetics, Koc University, Istanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Molecular Biology and Genetics, Koc University, Istanbul</wicri:regionArea>
<wicri:noRegion>Istanbul</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kavakli, Ibrahim Halil" sort="Kavakli, Ibrahim Halil" uniqKey="Kavakli I" first="Ibrahim Halil" last="Kavakli">Ibrahim Halil Kavakli</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Chemical and Biological Engineering, Koc University, Istanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Chemical and Biological Engineering, Koc University, Istanbul</wicri:regionArea>
<wicri:noRegion>Istanbul</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Biology and Genetics, Koc University, Istanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Molecular Biology and Genetics, Koc University, Istanbul</wicri:regionArea>
<wicri:noRegion>Istanbul</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of biomolecular structure & dynamics</title>
<idno type="eISSN">1538-0254</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Despite strict measures taken by many countries, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be an issue of global concern. Currently, there are no clinically proven pharmacotherapies for coronavirus disease 2019, despite promising initial results obtained from drugs such as azithromycin and hydroxychloroquine. Therefore, the repurposing of clinically approved drugs for use against SARS-CoV-2 has become a viable strategy. Here, we searched for drugs that target SARS-CoV-2 3C-like protease (3CL<sup>pro</sup>
) and viral RNA-dependent RNA polymerase (RdRp) by in silico screening of the U.S. Food and Drug Administration approved drug library. Well-tolerated and widely used drugs were selected for molecular dynamics (MD) simulations to evaluate drug-protein interactions and their persistence under physiological conditions. Tetracycline, dihydroergotamine, ergotamine, dutasteride, nelfinavir, and paliperidone formed stable interactions with 3CL<sup>pro</sup>
 based on MD simulation results. Similar analysis with RdRp showed that eltrombopag, tipranavir, ergotamine, and conivaptan bound to the enzyme with high binding free energies. Docking results suggest that ergotamine, dihydroergotamine, bromocriptine, dutasteride, conivaptan, paliperidone, and tipranavir can bind to both enzymes with high affinity. As these drugs are well tolerated, cost-effective, and widely used, our study suggests that they could potentially to be used in clinical trials for the treatment of SARS-CoV-2-infected patients. Communicated by Ramaswamy H. Sarma.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32752938</PMID>
<DateRevised><Year>2021</Year>
<Month>05</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-0254</ISSN>
<JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year>
<Month>Aug</Month>
<Day>05</Day>
</PubDate>
</JournalIssue>
<Title>Journal of biomolecular structure & dynamics</Title>
<ISOAbbreviation>J Biomol Struct Dyn</ISOAbbreviation>
</Journal>
<ArticleTitle>In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials.</ArticleTitle>
<Pagination><MedlinePgn>1-20</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/07391102.2020.1802346</ELocationID>
<Abstract><AbstractText>Despite strict measures taken by many countries, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be an issue of global concern. Currently, there are no clinically proven pharmacotherapies for coronavirus disease 2019, despite promising initial results obtained from drugs such as azithromycin and hydroxychloroquine. Therefore, the repurposing of clinically approved drugs for use against SARS-CoV-2 has become a viable strategy. Here, we searched for drugs that target SARS-CoV-2 3C-like protease (3CL<sup>pro</sup>
) and viral RNA-dependent RNA polymerase (RdRp) by in silico screening of the U.S. Food and Drug Administration approved drug library. Well-tolerated and widely used drugs were selected for molecular dynamics (MD) simulations to evaluate drug-protein interactions and their persistence under physiological conditions. Tetracycline, dihydroergotamine, ergotamine, dutasteride, nelfinavir, and paliperidone formed stable interactions with 3CL<sup>pro</sup>
 based on MD simulation results. Similar analysis with RdRp showed that eltrombopag, tipranavir, ergotamine, and conivaptan bound to the enzyme with high binding free energies. Docking results suggest that ergotamine, dihydroergotamine, bromocriptine, dutasteride, conivaptan, paliperidone, and tipranavir can bind to both enzymes with high affinity. As these drugs are well tolerated, cost-effective, and widely used, our study suggests that they could potentially to be used in clinical trials for the treatment of SARS-CoV-2-infected patients. Communicated by Ramaswamy H. Sarma.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gul</LastName>
<ForeName>Seref</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Chemical and Biological Engineering, Koc University, Istanbul, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ozcan</LastName>
<ForeName>Onur</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Department of Molecular Biology and Genetics, Koc University, Istanbul, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Asar</LastName>
<ForeName>Sinan</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Anesthesiology and Reanimation, Bakırköy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Okyar</LastName>
<ForeName>Alper</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology, Istanbul University Faculty of Pharmacy, Istanbul, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Barıs</LastName>
<ForeName>Ibrahim</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>Department of Molecular Biology and Genetics, Koc University, Istanbul, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kavakli</LastName>
<ForeName>Ibrahim Halil</ForeName>
<Initials>IH</Initials>
<AffiliationInfo><Affiliation>Department of Chemical and Biological Engineering, Koc University, Istanbul, Turkey.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Molecular Biology and Genetics, Koc University, Istanbul, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>08</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Biomol Struct Dyn</MedlineTA>
<NlmUniqueID>8404176</NlmUniqueID>
<ISSNLinking>0739-1102</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3 chymotrypsin like protease</Keyword>
<Keyword MajorTopicYN="N">RNA dependent RNA polymerase</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="N">drug repurposing</Keyword>
<Keyword MajorTopicYN="N">tetracycline</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>8</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32752938</ArticleId>
<ArticleId IdType="doi">10.1080/07391102.2020.1802346</ArticleId>
<ArticleId IdType="pmc">PMC7484590</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2020 May 21;64(6):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205349</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Core Evid. 2005;1(2):143-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22500150</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2019 May 28;10(1):2342</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31138817</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Oncol. 2014 Jan 20;32(3):229-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24323034</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Metab Syndr Obes. 2010 Mar 26;3:43-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21437075</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Occup Environ Med. 2020 Feb 5;11(2):65-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020915</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Mar;579(7798):270-273</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32015507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2007 Dec;6(12):1001-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18049474</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Pharm Sin B. 2020 May;10(5):766-788</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32292689</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2020 Jun 23;64(7):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32366720</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2012 Jul;93(Pt 7):1385-1409</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22535777</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Indian J Pharmacol. 2020 Jan-Feb;52(1):56-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32201449</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2015 Aug 7;290(32):19403-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26055715</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2011 Apr 21;364(16):1523-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21410387</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(2):e31787</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22355395</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2020 Mar 13;295(11):3518-3531</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32019867</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Graph. 1996 Feb;14(1):33-8, 27-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8744570</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Struct Dyn. 2020 May 12;:1-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32340562</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Metab Dispos. 2011 Sep;39(9):1734-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21646437</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Neurol. 2003;49(1):20-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12464714</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Clin Pract Urol. 2006 Sep;3(9):495-503</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16964191</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>World J Clin Cases. 2020 Jun 6;8(11):2325-2331</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32548163</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2020 Jan;173:104668</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31786251</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs. 2017 Dec;77(18):1935-1966</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29143192</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FEMS Microbiol Lett. 2015 Nov;362(22):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26459887</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Microbiol. 2004 Aug;7(4):412-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15358261</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Comput Chem. 2005 Dec;26(16):1781-802</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16222654</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Korean Med Sci. 2020 Feb 17;35(6):e79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32056407</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pathol. 2008 Jun;215(2):118-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18338334</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Stem Cells. 2009 Feb;27(2):424-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19038790</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biol Psychiatry. 2007 Dec 15;62(12):1363-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17601495</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Top Microbiol Immunol. 2005;287:57-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15609509</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Struct Dyn. 2020 Jun 1;:1-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32396767</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2006 Aug;58(2):256-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16816396</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Urol. 2003 Jul;44(1):82-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12814679</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Cancer. 2017 Apr 15;140(8):1713-1726</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27870005</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Comput Chem. 2008 Aug;29(11):1859-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18351591</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Struct Dyn. 2021 May;39(8):2724-2732</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32266867</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mayo Clin Proc. 1999 Jul;74(7):727-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10405705</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FEMS Microbiol Lett. 2017 Sep 15;364(17):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28903466</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2006 Apr;117(1):17-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16503362</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chem Inf Model. 2005 Jan-Feb;45(1):177-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15667143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med. 2001 May;110(7):594</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11347624</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Comput Chem. 2010 Jan 30;31(2):455-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19499576</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 Jun 13;300(5626):1763-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12746549</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med Sci. 2009 Jan;337(1):28-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19057376</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Oncol. 2013 Sep;25(5):495-502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23872785</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2003 Sep;84(Pt 9):2305-2315</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12917450</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Headache. 1997;37 Suppl 1:S15-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9009470</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Endocrinol Metab. 2004 May;89(5):2179-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15126539</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem. 2015 Sep 1;23(17):6036-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26190463</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Microbiol. 2016 Jun;24(6):490-502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27012512</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2014 Apr;159(4):711-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24142271</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neuropsychiatr Dis Treat. 2007 Dec;3(6):869-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19300622</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2008 Apr;133(1):88-100</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17397959</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2017 May;141:29-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28185815</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2003 Dec 15;31(24):7117-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14654687</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Struct Dyn. 2021 May;39(8):2679-2692</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32266873</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2019 Jul 2;47(W1):W636-W641</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30976793</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Urology. 2002 Sep;60(3):434-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12350480</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Endocrinol Metab. 2006 Jun;91(6):2145-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16522696</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Oct;92(10):2087-2095</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32374457</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Exp Med Biol. 2006;581:609-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17037607</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Struct Dyn. 2020 May 13;:1-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32362245</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2016 Jul;131:141-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27181378</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Struct Dyn. 2020 Apr 30;:1-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32306836</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Comput Chem. 2017 Jun 5;38(21):1879-1886</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28497616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 1999 Mar 17;281(11):987</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10086430</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Methods. 2017 Jan;14(1):71-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27819658</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Neurol. 2002;47(2):99-107</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11844898</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Jun 4;318(3):719-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15144898</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Ther. 2006 Aug;28(8):1065-1078</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16982285</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Mar;579(7798):265-269</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32015508</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2017 Sep;145:33-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28712942</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Turquie</li>
</country>
</list>
<tree><country name="Turquie"><noRegion><name sortKey="Gul, Seref" sort="Gul, Seref" uniqKey="Gul S" first="Seref" last="Gul">Seref Gul</name>
</noRegion>
<name sortKey="Asar, Sinan" sort="Asar, Sinan" uniqKey="Asar S" first="Sinan" last="Asar">Sinan Asar</name>
<name sortKey="Bar S, Ibrahim" sort="Bar S, Ibrahim" uniqKey="Bar S I" first="Ibrahim" last="Bar S">Ibrahim Bar S</name>
<name sortKey="Kavakli, Ibrahim Halil" sort="Kavakli, Ibrahim Halil" uniqKey="Kavakli I" first="Ibrahim Halil" last="Kavakli">Ibrahim Halil Kavakli</name>
<name sortKey="Kavakli, Ibrahim Halil" sort="Kavakli, Ibrahim Halil" uniqKey="Kavakli I" first="Ibrahim Halil" last="Kavakli">Ibrahim Halil Kavakli</name>
<name sortKey="Okyar, Alper" sort="Okyar, Alper" uniqKey="Okyar A" first="Alper" last="Okyar">Alper Okyar</name>
<name sortKey="Ozcan, Onur" sort="Ozcan, Onur" uniqKey="Ozcan O" first="Onur" last="Ozcan">Onur Ozcan</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001077 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001077 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32752938
   |texte=   In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32752938" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials.

In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki